Cite
MLA Citation
Stefano Del Prato et al.. “Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.” Lancet, vol. 398, no. 10313, 2021, pp. 1811–1824. http://access.bl.uk/ark:/81055/vdc_100145643701.0x000050